Licences obligatoires de médicaments pour les pays connaissant des problèmes de santé publique : mythe ou réalité juridiques ?

The 2003 “waiver” (decision of the General Council of WTO of 30 August 2003), after the Doha Declaration in TRIPS and Health in 2001, that authorized governments from licensing the production of generic versions of patented drugs exclusively for export to countries unable to make the medicines, had been adopted by an European Union Regulation in 2006. Predicted for an easier access to generic versions of patented drugs, the results of this specific procedure has been disappointing, since it has only been used once.